Member Info for Cashintime

Lilly CEO David Hicks comments at JPM 24 healthcare San Francisco that his door is "open for business" for small start up Bio tech companies.

I hope he looks our way.

https://www.fiercebiotech.com/biotech/jpm24-lilly-ceo-david-ricks-biotechs-were-open-business

If he gets a deal away, we will get him a golden Papermate in a case.

Will we get a deal away in San Francisco.

Our CFO a founding member of Poolbeg along side Cathal Friel is in attendance and has his bic biro in pocket.

CF must have a reverse merger agreement in the making to bring us to Nasdaq and hopefully we will be on the road to be the £1B market cap company that will hopefully without too much dilution.

It is looking like we will follow Hvivo rise as it will spark interest from new investors that will begin to see that the Poolbeg model will reap rewards in 2024.

Https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.share-talk.com/week-in-small-caps-24-stocks-for-2024-zaks-traders-cafe/&ved=2ahUKEwix8KGYtL6DAxX3WEEAHWlUAb4QFnoECB4QAQ&usg=AOvVaw0EtS6oDyOSVEnj3kBxdgKk

Happy new year to all.Zac gives us a price target of 20p with a stop loss of 7p which is well believable and we have the prospect of doing alot better.

Hvivo off to a flying start this year and I hope that we follow suit. Bring on a series of deals. I don't think that we will have to wait too long.

2024 will be a pivoting year here in Poolbeg Pharma.

What's in store is Sanderscam cleaning out this company for another grand a day while achieving nothing. £100m spent , what is it a half a trillion of confetti shares a a multitude of forward sold batches will be issued again this year as we await our latest fairy story. Anybody thinking of investing here should do a bit of research even if it to flick through quickly the RNS's from the last couple of years. Sanderscam cannot face the shareholders anymore out of pure shame but continues to raise to keep himself in massive wages. Massive amounts of millions have been squandered God only knows where. He needs investigating to see if he has confirmed to company law and prosecuted if everything is not found to be above board on the accounts.

We didn't get an end of year statement last year,maybe this year might be a good time to release progress and hint on milestones timelines for 2024.

Our new team will hit the ground running 2024 . We will be looking at closing deals and recycling the revenue generated into new and exciting projects. Things will happen fast if we are to become a 1b+ market cap.

Same as the June 29th RNS. No further details given really. Positive results but we need IP closed off to protect us from copycats I presume.

Https://finance.yahoo.com/news/pfizer-completes-acquisition-seagen-123900980.html

It looks like Pfizer is becoming the major Oncology player in the market.

Polb 001 would compliment many of their cancer treatments for sure. We must be on their radar.

Another late reported trade of 500,000 @ 9.10p , a regular occurrence of late.

We could have that AI RNS tomorrow morning. I don't think that they will leave it until the wind down week before Christmas.

I agree and in many cases it could prove to be a lifesaver for our nearest and dearest.

Afternoon Spuddy, I think that they will license 001 multiple times for a specific use that will be protected by Poolbegs IP. We all know that CRS blocker can have many uses as RSV , Oncology and Sepsis etc and more than likely others that suit short term use.

With regards to an upfront payment I would think that we should not set our sights to being more than £10m or we may be disappointed.

The real riches will come with forwards milestones and future royalties down the line and these could easily be in the hundreds of millions or maybe in the case of a major buy out 1b+ as has been hinted by the company lately. The wheels are obviously in motion and we are told we are on a pivot point to being revenue generating. Something is being finalised and we will know shortly.

Maybe the Oncology trials in H1 2024 will be financed with a MOU attached. We are holding up well lately and as seen by Hvivo yesterday our sister company weather we like it or not ,we play with the big boys and the money is there for a proven product.

AI more detailed news that identified new drug targets was promised by years end and I think could well come tomorrow.

Pfizer's purchase of Seagen for $43b will expand their portfolio into the oncology space. They may well be the entity that suggested us to explore the oncology angle for 001. If so it will be a blockbuster for them and compliment their oncology expansion that is due to bring multi billions yearly to their balance sheet which they dearly require with plummeted vaccine revenues. With them buying into Cytoreason with a $100m stake they are well aware of our product ranges suitably to their new focus.

Sanderson out now, enough is enough. The man is a scam artist. He is ashamed of facing the shareholders but lose that shame when it is time to pick up his "bag of sand" a day in remuneration.

More shares in this company in than people in the world. He has cost alot of people alot of money by his lies and I have no doubt that karma will come knocking at his door. DL back again is just unbelievable. One couldn't make it up.

Another late reported trade of 500,000 from this morning showing appetite once more for this share.

We should be getting more details of the Cytoreason AI results before years end so probably this week.

I think that they are letting us know that there is "serious" interest from potential partners and it is just a matter of getting a collaborative deal over the line. I am positive that this company will be a success and the rewards may be great so I will continue to hold as I see the company model progress as planned. We have a great team in place now for execution of a few deals in the near future.

Thanks Beau,

Cathal very focused on making Poolbeg work. In his own words he sees revenues coming in within 3,4 or 5 months. He genuinely sees this becoming a Billion market cap company. I am happy to come along for the journey.